Novel biomarkers and the future of targeted therapies in cholangiocarcinoma: a narrative review.

ABSTRACT:

Background and objectives

Cholangiocarcinoma is a highly aggressive and heterogenous group of biliary malignancies arising from any site in the biliary tree, comprising 15% of all primary liver cancers. The nature of the disease and nonspecific presentation leads to late diagnosis and ultimately poor outcomes for patients. Combination gemcitabine and cisplatin has been the standard of care for cholangiocarcinoma (CCA) since 2010, with a median overall survival of 11.7 months. The five-year survival for CCA remains 5-10%, revealing a clear need for improved treatment options.

Methods

This targeted review highlights the role of next generation sequencing in CCA and the clinically relevant tumor biomarkers that have become the focus of therapeutic development.

Key content an

SUBMITTER: Munugala N 

PROVIDER: S-EPMC9023822 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature